Aandeel CRXM GENE BIOTHERAPEUTICS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Gene Biotherapeutics, Inc.

Aandelen

CRXM

US8767671048

Beurs gesloten - OTC Markets
Andere beurzen
 15:30:01 17-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,000001 USD -.--% Intraday-grafiek van Gene Biotherapeutics, Inc. -.--% -.--%
2022 Gene Biotherapeutics, Inc. Accountant trekt 'Going Concern' in twijfel CI
2021 Gene Biotherapeutics, Inc. maakt winstcijfers bekend voor het eerste kwartaal eindigend op 31 maart 2020 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
GENE BIOTHERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
GENE BIOTHERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K/A)
GENE BIOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)
GENE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
Gene Biotherapeutics, Inc. Announces Resignation of Murray H. Hutchison from the Board
GENE BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Gene Biotherapeutics Inc. Enters into an Agreement with Fujifilm Diosynth Biotechnologies to Manufacture the Generx Angiogenic Gene Therapy Product
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
GENE BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Gene Biotherapeutics, Inc. Announces Management Changes
Gene Biotherapeutics, Inc. Appoints James L. Grainer as Chief Financial Officer
Gene Biotherapeutics, Inc. announced that it has received $1.7 million in funding from Nostrum Pharmaceuticals LLC
Gene Biotherapeutics Inc. Announces Retirement of Gerald J. Lewis from its Board of Directors
Gene Biotherapeutics Inc. Enters into an Agreement with the Olaregen Therapeutix Inc
Gene Biotherapeutics Mulls Acquisitions
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers CRXM
  4. Nieuws Gene Biotherapeutics, Inc.
  5. Andere talen